Pair may improve glycemic control and allow for reduction in insulin dose without significantly increasing hypoglycemia.
Read More »Strategies for the Practical Management of Type 2 Diabetes Part 4
In this week's Homerun Slides, the conclusion of type 2 diabetes management strategies. Two case studies show the role of DPP-4 and SGLT-2/DPP-4 combo treatments.
Read More »Dr. Claude Lardinois Part 2 – SGLT-2 and Amputations
Dr. Claude Lardinois talks with Diabetes in Control Associate Medical Editor Joy Pape at the 2016 AACE Meeting. In part 2 of this Exclusive Interview, Dr. Lardinois explains his emphasis on the importance of quitting smoking to decrease the risk of amputations. Dr. Claude Lardinois, M.D., FACP, FACE, MACN, has …
Read More »Updates on Diabetes Trials, Old and New
Early intervention in treating diabetes has shown long term benefits, follow-up data for both old and new studies show.
Read More »The Impact of Genetics in Cardiovascular Disease
In this exclusive interview, Dr. Claude Lardinois discusses genetic risk factors for cardiovascular issues in diabetes patients, the impact of smoking on amputations, and why albumin is a driver of cardiovascular disease.
Read More »Did You Know: What Are the SGLT-2 Inhibitor Trade-offs?
The overall profile of sodium-glucose cotransporter 2 inhibitors suggests they are a reliable, second-line therapy choice for adults with type 2 diabetes. However, the class is associated with possible side effects that should be carefully considered, according to a Dr. George L. Bakris, MD, director of the ASH Comprehensive Hypertension Center at the University of Chicago Medicine at a recent presentation at the Cardiometabolic Health Congress. Dr. Bakris stated that they definitely are preferred second-line agents, absolutely over sulfonylureas, and probably over thiazolidinediones and some other agents as well.
Read More »Comparing Canagliflozin and Glimepiride in Attaining Quality Measures
How do these drugs compare in achieving updated diabetes-related quality measures?
Read More »What to Do If Metformin Fails To Get Patients To Target
Combination therapy resulting in superior glycemic control, weight loss versus either agent alone
Read More »New SGLT-2, Ertugliflozin Shows Promising Results for Diabetes Management
Ertugliflozin provides clinically significant reductions in blood glucose levels.
Read More »Expanding the Role of Canagliflozin in the Elderly
What benefits can medication provide in elderly patients with uncontrolled type 2?
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.